keyword
https://read.qxmd.com/read/38132158/lipophilic-statins-eliminate-senescent-endothelial-cells-by-inducing-anoikis-related-cell-death
#21
JOURNAL ARTICLE
Barbora Belakova, Nicholas K Wedige, Ezzat M Awad, Simon Hess, André Oszwald, Marlene Fellner, Shafaat Y Khan, Ulrike Resch, Markus Lipovac, Karel Šmejkal, Pavel Uhrin, Johannes M Breuss
Pre-clinical studies from the recent past have indicated that senescent cells can negatively affect health and contribute to premature aging. Targeted eradication of these cells has been shown to improve the health of aged experimental animals, leading to a clinical interest in finding compounds that selectively eliminate senescent cells while sparing non-senescent ones. In our study, we identified a senolytic capacity of statins, which are lipid-lowering drugs prescribed to patients at high risk of cardiovascular events...
December 14, 2023: Cells
https://read.qxmd.com/read/38115091/statins-and-cognitive-decline-in-patients-with-alzheimer-s-and-mixed-dementia-a-longitudinal-registry-based-cohort-study
#22
JOURNAL ARTICLE
Bojana Petek, Henrike Häbel, Hong Xu, Marta Villa-Lopez, Irena Kalar, Minh Tuan Hoang, Silvia Maioli, Joana B Pereira, Shayan Mostafaei, Bengt Winblad, Milica Gregoric Kramberger, Maria Eriksdotter, Sara Garcia-Ptacek
BACKGROUND: Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer's disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. OBJECTIVE: To explore the association between the use of lipid-lowering medications and cognitive decline over time in a cohort of patients with AD or mixed dementia with indication for lipid-lowering treatment...
December 20, 2023: Alzheimer's Research & Therapy
https://read.qxmd.com/read/38112932/influence-of-a-short-course-of-ritonavir-used-as-booster-in-antiviral-therapies-against-sars-cov-2-on-the-exposure-of-atorvastatin-and-rosuvastatin
#23
JOURNAL ARTICLE
Evelyn Krohmer, Brit Silja Rohr, Felicitas Stoll, Katja S Gümüs, Mariano Bergamino, Gerd Mikus, Max Sauter, Jürgen Burhenne, Johanna Weiss, Andreas D Meid, David Czock, Antje Blank, Walter E Haefeli
PURPOSE: Early antiviral treatment with nirmatrelvir/ritonavir is recommended for SARS-CoV-2-infected patients at high risk for severe courses. Such patients are usually chronically ill and susceptible to adverse drug interactions caused by ritonavir. We investigated the interactions of short-term low-dose ritonavir therapy with atorvastatin and rosuvastatin, two statins commonly used in this population. METHOD: We assessed exposure changes (area under the concentration-time curve (AUC∞ ) and maximum concentration (Cmax )) of a single dose of 10 mg atorvastatin and 10 mg rosuvastatin before and on the fifth day of ritonavir treatment (2 × 100 mg/day) in healthy volunteers and developed a semi-mechanistic pharmacokinetic model to estimate dose adjustment of atorvastatin during ritonavir treatment...
December 19, 2023: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/38087774/unveiling-the-rare-complication-statin-induced-immune-mediated-necrotizing-myopathy
#24
JOURNAL ARTICLE
Farheen Hussain Chowdhury, Olena Mahneva, Maniekha Maharaj, Werther Marciales
BACKGROUND Statin-induced necrotizing autoimmune myopathy is an exceptionally rare yet severe complication of statin therapy that may develop in individuals at any time during their exposure to statins. The development of proximal muscle weakness, muscle pain, and elevated creatine kinase (CK) levels in patients while taking statins should prompt clinical consideration of statin-induced myopathy. The pathophysiology arises from the production of auto-antibodies, which target the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) enzyme, leading to the aggressive breakdown of myofibrils...
December 13, 2023: American Journal of Case Reports
https://read.qxmd.com/read/38061370/efficacy-and-safety-of-bempedoic-acid-among-patients-with-and-without-diabetes-prespecified-analysis-of-the-clear-outcomes-randomised-trial
#25
RANDOMIZED CONTROLLED TRIAL
Kausik K Ray, Stephen J Nicholls, Na Li, Michael J Louie, Danielle Brennan, A Michael Lincoff, Steven E Nissen
BACKGROUND: Statins reduce LDL cholesterol and cardiovascular events among those with or without diabetes but have been reported to increase new-onset diabetes. The CLEAR Outcomes trial demonstrated that bempedoic acid reduced the risk of major adverse cardiovascular events among statin-intolerant patients at high cardiovascular risk. In this prespecified analysis, our dual aims were to evaluate the cardiovascular benefits of bempedoic acid, an ATP-citrate lyase inhibitor, in individuals with diabetes, and to evaluate the risk of new-onset diabetes and HbA1c among those without diabetes in the CLEAR Outcomes trial...
January 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38041072/methodology-and-results-of-cost-effectiveness-of-ldl-c-lowering-with-evolocumab-in-patients-with-acute-myocardial-infarction-in-china
#26
JOURNAL ARTICLE
Yuansheng Wan, Jinyu Liu, Xiaolian Zhan, Yu Zhang, Ruxu You
BACKGROUND: According to the Chinese guidelines for lipid management (2023), evolocumab in combination with statins was recommended as secondary prevention of cardiovascular disease. However, because of the variation in the price of evolocumab and its different methods of confirming clinical efficacy, it was necessary to explore its economics and the impact of different methods of confirming efficacy on its economic studies. OBJECTIVE: The purpose of this paper was to assess the cost-effectiveness of evolocumab with statins versus statins alone for patients with acute myocardial infarction(AMI) in China and to investigate the impact of different clinical effectiveness modeling approaches on economic outcomes...
December 1, 2023: Cost Effectiveness and Resource Allocation: C/E
https://read.qxmd.com/read/38030791/the-ror%C3%A9-srebp2-pathway-is-a-master-regulator-of-cholesterol-metabolism-and-serves-as-potential-therapeutic-target-in-t-4-11-leukemia
#27
JOURNAL ARTICLE
Estelle Erkner, Thomas Hentrich, Rebekka Schairer, Rahel Fitzel, Kathy-Ann Secker-Grob, Johan Jeong, Hildegard Keppeler, Fulya Korkmaz, Julia M Schulze-Hentrich, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind
Dysregulated cholesterol homeostasis promotes tumorigenesis and progression. Therefore, metabolic reprogramming constitutes a new hallmark of cancer. However, until today, only few therapeutic approaches exist to target this pathway due to the often-observed negative feedback induced by agents like statins leading to controversially increased cholesterol synthesis upon inhibition. Sterol regulatory element-binding proteins (SREBPs) are key transcription factors regulating the synthesis of cholesterol and fatty acids...
November 29, 2023: Oncogene
https://read.qxmd.com/read/37970855/-can-a-lipophilic-statin-improve-the-treatment-of-heart-failure-with-preserved-ejection-fraction-in-patients-with-hypertension-and-obesity
#28
JOURNAL ARTICLE
Yu A Vasyuk, E Yu Shupenina, G A Namazova, A I Zavyalova
AIM: To evaluate the effect of pleiotropic (anti-inflammatory and antifibrotic) effects of a lipophilic statin (atorvastatin) in the treatment of heart failure (HF) with preserved left ventricular (LV) ejection fraction (HFpEF)Material and methods. This observational study included 80 patients with HFpEF; 40 of them received atorvastatin 20-80 mg/day in addition to a standard treatment. 40 patient who refused of the statin treatment or had intolerance of the drug received only the standard treatment...
November 8, 2023: Kardiologiia
https://read.qxmd.com/read/37933122/optimizing-statin-therapy-for-primary-prevention-of-cardiovascular-disease-in-type-2-diabetes-mellitus-patients-exploring-dose-class-and-intensity
#29
JOURNAL ARTICLE
Jung-Min Yu, Wan-Ming Chen, Ben-Chang Shia, Szu-Yuan Wu
PURPOSE: To investigate the impact of statin use on primary prevention of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) in a dose-, class-, and use intensity-dependent manner. METHODS: We used an inverse probability treatment-weighted Cox hazards model, with statin use status as a time-dependent variable. RESULTS: Our results showed that statin use was associated with a significant reduction in CVD risk with an adjusted hazard ratio of 0...
2023: Diabetes & Vascular Disease Research
https://read.qxmd.com/read/37900543/rhabdomyolysis-in-a-long-term-statin-user-without-traditional-risk-factors-a-case-report
#30
Hiroyuki Naritaka, Yoshitaka Aoki, Yukako Obata, Soichiro Mimuro, Yoshiki Nakajima
We report a rare case of rhabdomyolysis in a 64-year-old man who had been receiving long-term statin therapy for hyperlipidemia. The patient initially presented with symptoms of acute appendicitis, which later progressed to acute renal failure and rhabdomyolysis. No commonly identified risk factors for rhabdomyolysis, including drug interactions and statin doses, were observed. The patient was urgently admitted to the intensive care unit where the relevant medications were discontinued in a timely manner and infusion resuscitation was performed...
September 2023: Curēus
https://read.qxmd.com/read/37835033/national-trends-in-the-use-of-state-reimbursed-lipid-lowering-medications-in-latvia-2012-2021
#31
JOURNAL ARTICLE
Arturs Praskilevics, Inga Urtane, Gustavs Latkovskis
BACKGROUND: We aimed to estimate the trends in dispensing rate and the spectrum of all state-funded lipid-lowering medications (LLMs) in Latvia over a decade. METHODS: Using data from the National Health Service of the Republic of Latvia, we retrospectively analyzed all dispensed LLM-containing drug units in a ten-year period from 2012 to 2021. RESULTS: In Latvia, 318.2 million oral and 994 subcutaneous units of LLMs were dispensed over a decade...
October 6, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/37819392/rosuvastatin-but-not-atorvastatin-enhances-the-antihypertensive-effect-of-cilostazol-in-an-acute-model-of-hypertension
#32
JOURNAL ARTICLE
Ahmed Hamdy, Hany M El-Bassossy, Shimaa M Elshazly, Shaimaa S El-Sayed
PURPOSE: Hypertensive emergency, a sudden and severe increase in blood pressure, necessitates immediate intervention to avoid end-organ damage. Cilostazol, a selective phosphodiesterase-III inhibitor, has vasodilator effect. Here, we investigated the effect of two commonly used statins, atorvastatin or rosuvastatin, on cilostazol antihypertensive activity in acute model of hypertension. METHODS: Hypertensive emergency was induced via angiotensin II intravenous infusion (120 ng...
October 11, 2023: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/37784789/association-of-left-anterior-descending-coronary-artery-calcium-progression-and-radiation-dose-with-major-adverse-cardiac-events-in-breast-cancer
#33
JOURNAL ARTICLE
J O Gasho, K Silos, C V Guthier, S C Zhang, M Burnison, A J Mirhadi, J K Jang, S L Shiao, M Kamrava, J Steers, E McKenzie, B Tamarappoo, D Ouyang, A C Kwan, A Nikolova, R H Mak, K M Atkins
PURPOSE/OBJECTIVE(S): Coronary artery calcium (CAC) is associated with increased risk of major adverse cardiac events (MACE). Accelerated CAC progression has been observed in patients with breast cancer after radiotherapy (RT) and there is a relationship between left anterior descending (LAD) coronary artery RT dose and the risk of coronary events. However, there is lack of consensus on LAD dose constraints for breast RT and limited data on the extent and impact of CAC progression. Our objective was to evaluate the association of LAD dose exposure and CAC progression with the risk of MACE in patients with breast cancer following RT...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37781714/the-impact-of-statin-use-before-intensive-care-unit-admission-on-patients-with-acute-kidney-injury-after-cardiac-surgery
#34
JOURNAL ARTICLE
Shishi Li, Youlin Zhang, Yan Yang, Sining Chen, Zhiqian Yang, Chaoying Kuang, Yuzhen Zhong, Fanna Liu
Background: Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common and serious complication after cardiac surgery. The influence of statin use before surgery on the renal outcome of patients undergoing cardiac surgery is controversial. The purpose of this study was to evaluate the effect of statins on postoperative renal outcomes in patients undergoing cardiac surgery. Methods: We included CSA-AKI patients in the Medical Information Mart for Intensive Care (MIMIC)-IV database and were divided into statin group and non-statin group according to whether they used statins before entering intensive care units (ICU)...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37775612/contribution-of-intestinal-triglyceride-rich-lipoproteins-to-residual-atherosclerotic-cardiovascular-disease-risk-in-individuals-with-type-2-diabetes-on-statin-therapy
#35
JOURNAL ARTICLE
Marja-Riitta Taskinen, Niina Matikainen, Elias Björnson, Sanni Söderlund, Jussi Inkeri, Antti Hakkarainen, Helka Parviainen, Carina Sihlbom, Annika Thorsell, Linda Andersson, Martin Adiels, Chris J Packard, Jan Borén
AIMS/HYPOTHESIS: This study explored the hypothesis that significant abnormalities in the metabolism of intestinally derived lipoproteins are present in individuals with type 2 diabetes on statin therapy. These abnormalities may contribute to residual CVD risk. METHODS: To investigate the kinetics of ApoB-48- and ApoB-100-containing lipoproteins, we performed a secondary analysis of 11 overweight/obese individuals with type 2 diabetes who were treated with lifestyle counselling and on a stable dose of metformin who were from an earlier clinical study, and compared these with 11 control participants frequency-matched for age, BMI and sex...
December 2023: Diabetologia
https://read.qxmd.com/read/37754831/a-simple-strategy-to-reduce-contrast-media-use-and-risk-of-contrast-induced-renal-injury-during-pci-introduction-of-an-optimal-contrast-volume-protocol-to-daily-clinical-practice
#36
JOURNAL ARTICLE
Aiste Zebrauskaite, Greta Ziubryte, Lukas Mackus, Austeja Lieponyte, Evelina Kairyte, Ramunas Unikas, Gediminas Jarusevicius
Contrast-induced acute kidney injury is the leading cause of iatrogenic acute nephropathy. Development of contrast-induced nephropathy (CIN) increases the risk of adverse long- and short-term patients outcomes, the hospital costs, and length of hospitalization. There are a couple of methods described for CIN prevention (statin prescription, prehydration, contrast media (CM) clearance from the blood system, and decrease amounts of contrast volume). The CM volume to patient's creatinine clearance ratio is the main factor to predict the risk of CIN development...
September 19, 2023: Journal of Cardiovascular Development and Disease
https://read.qxmd.com/read/37742031/development-of-a-sustainable-multianalyte-mekc-method-for-quantitation-of-the-antihyperlipidemic-drugs-ezetimibe-together-with-three-statins-greenness-and-whiteness-appraisal-studies
#37
JOURNAL ARTICLE
Haydi S Elbordiny, Sohila M Elonsy, Hoda G Daabees, Tarek S Belal
Implementing powerful and sustainable research that complies with green analytical chemistry (GAC) and white analytical chemistry (WAC) fundamentals can downsize the environmental compliance costs and fruitfully affects practical and economic issues. Within this framework, rapid and white analytical micellar electrokinetic capillary chromatography (MEKC) methodology was developed for the synchronized estimation of the antihyperlipidemic drugs Ezetimibe (EZE), Atorvastatin (ATO), Rosuvastatin (ROS) and Simvastatin (SIM)...
September 23, 2023: BMC chemistry
https://read.qxmd.com/read/37719573/dysphagia-a-case-report-of-an-atypical-presentation-of-statin-induced-necrotizing-myositis
#38
Michaela B Polmann, Richard I Suarez, Ali Saad, Kebir H Bedran
Statin medications act by inhibiting the enzyme hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR), thus decreasing hepatic cholesterol synthesis. They are considered the mainstay treatment of hypercholesterolemia due to their tremendous efficacy and mortality benefit. Although generally well tolerated, statins may adversely affect skeletal muscle resulting in side effects ranging from mild myalgia to life-threatening necrotizing myositis. Statin-induced necrotizing autoimmune myositis is a rare yet devastating adverse effect that may occur shortly after initiation of therapy or after several years of use...
August 2023: Curēus
https://read.qxmd.com/read/37705879/physicians-perceptions-and-beliefs-on-the-current-dyslipidemia-management-practices-within-saudi-arabia
#39
JOURNAL ARTICLE
Turky H Almigbal, Dina S Almunif, Eman Ali Deshisha, Hani Altaradi, Abdullah A Alrasheed, Mohammed A Batais, Khalid F Alhabib
BACKGROUND: Limited reports addressing physicians' understanding of the various low-density lipoprotein cholesterol (LDL-C) targets/statin intensity required for treating the various dyslipidemia patient populations in Saudi Arabia are available. Therefore, the current study assessed the perceptions and beliefs of practicing clinicians in Saudi Arabia regarding the current practice for management of dyslipidemia and potential perceived barriers to adherence to lipid guidelines encountered in their regular clinical practice...
October 2023: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/37650314/cost-effectiveness-of-adding-ezetimibe-and-or-pcsk9-inhibitors-to-high-dose-statins-for-secondary-prevention-of-cardiovascular-disease-in-chinese-adults
#40
JOURNAL ARTICLE
Yuliang Xiang, Lei Gan, Heyue Du, Qiukui Hao, Bert Aertgeerts, Sheyu Li, Ming Hu
OBJECTIVES: The latest international guideline recommended the add-on therapy of ezetimibe and PCSK9 inhibitors in selected people for the secondary prevention of cardiovascular diseases (CVDs). However, it remains unclear whether these regimens fit the Chinese healthcare system economically. METHODS: Based on the Chinese context, this simulation study evaluated four therapeutic strategies including the high-dose statin-only group, ezetimibe plus statin group, PCSK9 inhibitors plus statin group, and PCSK9 inhibitors plus ezetimibe plus statin group...
August 31, 2023: International Journal of Technology Assessment in Health Care
keyword
keyword
166601
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.